In order to actually make money through financial markets, activities probably need to be separate and distinct from socializing. This is to say that if you would like to use a teller machine to withdraw cash, the money has to come from somewhere. If that source is a trade of securities, then interaction with strangers who have different motives–that are not always benevolent–could actually result in closure of one’s account, rather than a stack of $20 bills.
For what it is worth to anyone else Tesla, the luxury electric vehicle maker that also owns a struggling solar energy business, has given me some profit via options (and I still own the stock). The gist of it is that media is rife with persons who are betting against the corporation, or selling its shares short, largely because of fiscal issues. While there is no opposition to short selling here, it tends to be a more difficult type of trade, and there is an abundance of persons who simply lose money pretending to be proficient at it.
Tesla is the type of company that promises a glimpse into the future. It might be compared to Amazon.com years ago, when it was still just an online bookseller. These types of firms can command the market’s highest valuation: they might not be profitable, but can simply issue stock at higher and higher prices. My current bet is that Tesla might issue stock at some time in the future at $450 per share, compared to the $340+ it currently trades at.
There could be some similarities to Etsy, only without all the incompetent securities trading. Malls, or brick and mortar locations, which are not nearly as popular as they used to be, have plenty of expensive furniture. Suppose for example, you go to Pier 1 Imports for a dining table. You can probably find an assortment of items, mostly composed of engineered wood, that perhaps originate in China. China’s exports are currently being penalized by tariffs. If you browse on Etsy, you can find a worker who handcrafts the product out of a genuine wood variety, that might be produced by a local sawmill, and it is essentially online entirely, with all the ease of payment processing.
To be concise, and avoid further detail, my account is currently long Etsy, which seems to be a gateway to the future, and short Pier 1 Imports. Both bets are small, and hedged. Confidence in the bet against Pier 1 is not high: it could wind up costing money.
Something entirely different is my bet on Achillion Pharmaceuticals. Its drug that takes down the alternative pathway of the complement system has shown the highest efficacy at treating C3 glomerulopathy. Optimistically, it will be safe, and any issues involving severe pyogenic infection can be prevented (otherwise the competing Chemocentryx product might be preferable; experimental products owned by Apellis and Amyndas might show competitive efficacy, but it is unclear how they would be any safer than eculizumab). The shares of publicly traded biotechnology companies can be volatile, their prices change severely. Hence stock options can be expensive. My trade is to sell the July $3 put and use the money to buy the September $2 put in exchange for a credit. If the stock went to exactly $2 per share my loss could approach $100 per spread. If the stock is at $3 or higher, I keep not only the credit but the puts that do not expire until September. If the stock somehow went to $0, there would actually be a profit of $100 per spread because the September puts would be worth nearly $200 each. If the stock is assigned to me at about $2.75 per share, I can then sell call options against the stock as to profit through the volatility.
For what it is worth to anyone else Tesla, the luxury electric vehicle maker that also owns a struggling solar energy business, has given me some profit via options (and I still own the stock). The gist of it is that media is rife with persons who are betting against the corporation, or selling its shares short, largely because of fiscal issues. While there is no opposition to short selling here, it tends to be a more difficult type of trade, and there is an abundance of persons who simply lose money pretending to be proficient at it.
Tesla is the type of company that promises a glimpse into the future. It might be compared to Amazon.com years ago, when it was still just an online bookseller. These types of firms can command the market’s highest valuation: they might not be profitable, but can simply issue stock at higher and higher prices. My current bet is that Tesla might issue stock at some time in the future at $450 per share, compared to the $340+ it currently trades at.
There could be some similarities to Etsy, only without all the incompetent securities trading. Malls, or brick and mortar locations, which are not nearly as popular as they used to be, have plenty of expensive furniture. Suppose for example, you go to Pier 1 Imports for a dining table. You can probably find an assortment of items, mostly composed of engineered wood, that perhaps originate in China. China’s exports are currently being penalized by tariffs. If you browse on Etsy, you can find a worker who handcrafts the product out of a genuine wood variety, that might be produced by a local sawmill, and it is essentially online entirely, with all the ease of payment processing.
To be concise, and avoid further detail, my account is currently long Etsy, which seems to be a gateway to the future, and short Pier 1 Imports. Both bets are small, and hedged. Confidence in the bet against Pier 1 is not high: it could wind up costing money.
Something entirely different is my bet on Achillion Pharmaceuticals. Its drug that takes down the alternative pathway of the complement system has shown the highest efficacy at treating C3 glomerulopathy. Optimistically, it will be safe, and any issues involving severe pyogenic infection can be prevented (otherwise the competing Chemocentryx product might be preferable; experimental products owned by Apellis and Amyndas might show competitive efficacy, but it is unclear how they would be any safer than eculizumab). The shares of publicly traded biotechnology companies can be volatile, their prices change severely. Hence stock options can be expensive. My trade is to sell the July $3 put and use the money to buy the September $2 put in exchange for a credit. If the stock went to exactly $2 per share my loss could approach $100 per spread. If the stock is at $3 or higher, I keep not only the credit but the puts that do not expire until September. If the stock somehow went to $0, there would actually be a profit of $100 per spread because the September puts would be worth nearly $200 each. If the stock is assigned to me at about $2.75 per share, I can then sell call options against the stock as to profit through the volatility.